Kenneth Shain

Publications

• A Comparison of Salvage Infusional Chemotherapy Regimens for Recurrent/refractory Multiple Myeloma
  Cancer. Jul, 2015  |   Pubmed ID: 26149422
• Evaluating Kinase ATP Uptake and Tyrosine Phosphorylation Using Multiplexed Quantification of Chemically Labeled and Post-translationally Modified Peptides
  Methods (San Diego, Calif.). Jun, 2015  |   Pubmed ID: 25782629
• An Open-label Phase I/II Study of Cyclophosphamide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Myeloma
  European Journal of Haematology. Jan, 2015  |   Pubmed ID: 25600676
• A Preclinical Assay for Chemosensitivity in Multiple Myeloma
  Cancer Research. Jan, 2014  |   Pubmed ID: 24310398
• Phase II Study of Pegylated Liposomal Doxorubicin, Low-dose Dexamethasone, and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma
  American Journal of Hematology. Jan, 2014  |   Pubmed ID: 24030918
• Sequence of Novel Agents in Multiple Myeloma: an Instrumental Variable Analysis
  Leukemia Research. Sep, 2013  |   Pubmed ID: 23809054
• Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Nov, 2012  |   Pubmed ID: 22988056
• Metastatic Myeloma?
  Blood. Jun, 2012  |   Pubmed ID: 22700691
• Bortezomib Salvage Followed by a Phase I/II Study of Bortezomib Plus High-dose Melphalan and Tandem Autologous Transplantation for Patients with Primary Resistant Myeloma
  British Journal of Haematology. Jun, 2012  |   Pubmed ID: 22449149
• Monitoring a Nuclear Factor-κB Signature of Drug Resistance in Multiple Myeloma
  Molecular & Cellular Proteomics : MCP. Nov, 2011  |   Pubmed ID: 21846842
• Clinical Outcomes of Patients with Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: a Single-institution Experience
  Clinical Lymphoma, Myeloma & Leukemia. Dec, 2011  |   Pubmed ID: 21813352
• Environmental-mediated Drug Resistance: a Target for Multiple Myeloma Therapy
  Expert Review of Hematology. Dec, 2009  |   Pubmed ID: 21082957
• Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma
  Cancer Research. Dec, 2009  |   Pubmed ID: 19934314
• Beta1 Integrin Adhesion Enhances IL-6-mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation
  Cancer Research. Feb, 2009  |   Pubmed ID: 19155309
• Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating C-FLIP
  Journal of Immunology (Baltimore, Md. : 1950). Feb, 2008  |   Pubmed ID: 18209050
• Stat3 Activity in Melanoma Cells Affects Migration of Immune Effector Cells and Nitric Oxide-mediated Antitumor Effects
  Journal of Immunology (Baltimore, Md. : 1950). Apr, 2005  |   Pubmed ID: 15778348
• Targeting the Bone Marrow Microenvironment in Hematologic Malignancies
  Seminars in Hematology. Apr, 2004  |   Pubmed ID: 15190509
• Regulation of the Innate and Adaptive Immune Responses by Stat-3 Signaling in Tumor Cells
  Nature Medicine. Jan, 2004  |   Pubmed ID: 14702634
• Genotypic and Phenotypic Comparisons of De Novo and Acquired Melphalan Resistance in an Isogenic Multiple Myeloma Cell Line Model
  Cancer Research. Nov, 2003  |   Pubmed ID: 14633719
• Regulation of Caspase Expression and Apoptosis by Adenomatous Polyposis Coli
  Cancer Research. Aug, 2003  |   Pubmed ID: 12907606
• Adhesion-mediated Intracellular Redistribution of C-Fas-associated Death Domain-like IL-1-converting Enzyme-like Inhibitory Protein-long Confers Resistance to CD95-induced Apoptosis in Hematopoietic Cancer Cell Lines
  Journal of Immunology (Baltimore, Md. : 1950). Mar, 2002  |   Pubmed ID: 11859150
• Multiple Myeloma: New Insights and Therapeutic Approaches
  Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2000  |   Pubmed ID: 11701540